Clinical Trial

Effect of SGLT2 Inhibitors on Anemic CKD Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-31.
Trial Details
NCT Number NCT07334145
Lead Sponsor Sohag University
Conditions Anemia in CKD Patients
Enrollment 60 participants
Start Date 2026-01-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-14